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Abstract
Cholesterol plays an essential role in normal embryogenesis and perturbations 
in its de novo synthesis are responsible for organ malformations  in the cholesterol 
biosynthesis defects. Ten distinct inherited disorders have been linked to different 
enzyme defects in the isoprenoid/cholesterol biosynthetic pathway: mevalonic 
aciduria, hyperimmunoglobulinemia syndrome, squalene synthase deficiency, 
lanosterol synthase deficiency, hydrops-ectopic calcification-moth-eaten 
(Greenberg) skeletal dysplasia, X-linked dominant chondrodysplasia punctata, 
congenital hemidysplasia with ichthyosiform erythroderma and limb defects 
syndrome, lathosterolosis, Smith-Lemli-Opitz syndrome and desmosterolosis. 
These Mendelian disorders are clinically heterogeneous with protean manifestations 
reflecting the important role of cholesterol, and its intermediary metabolites, in 
embryogenesis and development. Key clinical features commonly represented by 
the cholesterol biosynthesis defects include structural brain malformations, axial 
skeletal developmental anomalies and genital and cardiac malformations. The 
aetiology of the underlying pathophysiology is unclear and multifactorial but may 
be due to lowered cholesterol and/or the elevated, teratogenic levels of the interme-
diate sterol precursors. Herein, we will review clinical, biochemical and molecular 
aspects of the known human cholesterol biosynthesis defects.
Keywords: cholesterol biosynthesis defects, mevalonate, squalene, skeletal dysplasia, 
chondrodysplasia, Smith-Lemli-Opitz
1. Introduction
Cholesterol is essential for normal cellular function. All nucleated cells can 
synthesise cholesterol from acetyl-CoA in the isoprenoid biosynthesis pathway via 
enzymatic reactions that are localised to the endoplasmic reticulum. Isoprenoids 
function in a variety of important cellular processes, including cell growth and 
differentiation, protein glycosylation, as precursors of oxysterols, steroid hormones 
and bile, in mitochondrial electron transport and signal transduction pathways, 
especially that of the hedgehog pathway [1–3]. Cholesterol biosynthesis is divided 
into two major pathways: pre-squalene cholesterol synthesis and post-squalene 
cholesterol synthesis. Pre-squalene cholesterol synthesis contributes to both sterol 
and isoprenoid synthesis, whereas post-squalene cholesterol synthesis is a commit-
ted pathway to sterol and vitamin D synthesis [3].
Isoprenoid biosynthesis (Figure 1) begins with the C2 compound acetyl-CoA, 
which, via six subsequent enzyme reactions, is converted into isopentenyl-
pyrophosphate, the basic C5 isoprene unit used for synthesis of all subsequent 
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isoprenoids [3]. The first committed step to the production of sterol isoprenoids is 
C30 squalene (composed of 6 isoprene units) which, after cyclisation, is converted 
into C30 lanosterol (4,4,14-α-trimethyl-cholesta-8(9),24-dien-3β-ol) [4]. Following 
this transformation, cholesterol can be synthesised via one of two independent 
routes; the Bloch pathway [5] or the Kandutsch-Russell pathway [6]. Both pathways 
utilise the same enzymes, but in different orders in a tissue-dependent manner, 
leading to the formation of different intermediates [7]. C27 cholesterol is subse-
quently produced from lanosterol via a series of at least eight different enzyme 
reactions, including one demethylation at C14, two demethylations at C4, one 
isomerisation of the D8 [9] double bond to D7, three reductions of the D24, D14 and 
D7 double bonds and one desaturation between C-5 and C-6 [3].
Currently, 10 Mendelian disorders of cholesterol biosynthesis have been 
characterised, all with complex multisystem clinical phenotypes, supporting the 
importance of cholesterol in embryogenesis and development (see Figure 1 and 
Table 1). Currently, the only reported defects in the pre-squalene pathway are the 
mevalonate kinase deficiency allelic conditions of mevalonic aciduria (MA, OMIM 
610377) and hyper IgD syndrome (HIDS, OMIM 260960), squalene synthase 
deficiency (SQSD, OMIM 618156) and lanosterol synthase deficiency (LSS, OMIM 
600909). Six Mendelian diseases in the post-squalene pathway have been reported: 
hydrops-ectopic calcification-moth-eaten skeletal dysplasia (HEM, OMIM 215140), 
congenital hemidysplasia with ichthyosiform erythroderma and limb defects 
syndrome (CHILD, OMIM 308050), chondrodysplasia punctate 2 (CDPX2, OMIM 
302960), lathosterolosis (OMIM 607330), Smith-Lemli-Opitz syndrome (SLOS, 
OMIM 270440) and desmosterolosis (OMIM 602398). Improved understanding of 
molecular mechanisms associated with intracellular trafficking of cholesterol and 
regulation of key rate limiting steps in cholesterol synthesis (e.g. via the ubiquitin 
proteasome system) has generated opportunities for identification of other novel 
Mendelian defects associated with cholesterol homeostasis [8, 9].
Figure 1. 
Schematic representation of the human cholesterol biosynthesis pathway. HMG-CoA, 3-hydroxy-3-methyl-
glutaryl-coenzyme A; P, phosphate; PP, pyrophosphate; MA, mevalonic aciduria, HIDS, hyper IgD syndrome; 
SQSD, squalene synthase deficiency; LSS, lanosterol synthase deficiency; HEM, hydrops-ectopic calcification-
moth-eaten; CHILD, congenital hemidysplasia with ichthyosiform erythroderma and limb defects; CDPX2, 
X-linked chondrodysplasia punctate 2; SLOS, Smith-Lemli-Opitz syndrome.
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Syndrome OMIM Chromosome 
location
Gene Enzyme Key features Inheritance
MA 610377 12q24.11 MVK Mevalonate kinase Autoinflammatory flares, dysmorphia, DD, psychomotor 
retardation and hepatosplenomegaly
AR
HIDS 260960 12q24.11 MVK Mevalonate kinase Recurrent cyclical fevers and abdominal pain AR
SQSD 618156 8p23.1 FDFT1 Squalene synthase Dysmorphia, DD, male genital malformations, brain 
malformations, seizures and abnormal urine organic acids
AR
LSS 600909 21q22.3 LSS Lanosterol synthase Congenital cataracts and hypotrichosis AR
HEM skeletal 
dysplasia
215140 1q42.12 LBR 3β-hydroxysteroid-sterol Δ14-reductase Non-immune hydrops fetalis, stippling and erroneous 
calcification and dwarfism
AR
CHILD 308050 Xq28 NSDHL Sterol C4-demethylase aka 
3β-hydroxysteroid dehydrogenase
Unilateral ichthyosis, male-lethal, ipsilateral limb reduction XLD
CDPX2 302960 Xp11.22–23 EBP 3β-hydroxysteroid-Δ8-Δ7-sterol 
isomerase
Rhizomelia, calcific stippling cataracts XLD
Lathosterolosis 607330 11q23.3-q24.1 SC5DL 3β-hydroxysteroid-Δ5-desaturase Microcephaly, cataracts, poly and syndactyly, DD, II AR
SLOS 270400 11q13.4 DHCR7 7-dehydrocholesterol reductase 2–3 syndactyly, cleft palate, II, typical craniofacial stigmata AR
Desmosterolosis 602398 1p32.3 DHCR24 24-dehydrocholesterol reductase SLOS-like dysmorphia, CHD, microcephaly, DD, II AR
Table 1. 
Known human defects of cholesterol biosynthesis.
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Modulating flux through the cholesterol biosynthesis pathway has been of inter-
est for many years as a pharmacological treatment option for hypercholesterolemia. 
The statin family of drugs inhibit HMG-CoA reductase, the rate limiting step in the 
pre-squalene pathway, and similar efforts have focused on inhibitors of squalene 
synthase as this enzyme is the first committed step in cholesterol biosynthesis. 
Animal and human models of squalene synthase inhibitors generated a complex 
array of farnesol-derived metabolites [10–12], the recognition of which was instru-
mental in describing SQSD, a newly described pre-squalene cholesterol biosynthe-
sis defect [4]. That pathogenesis of the cholesterol biosynthesis defects is complex, 
reflective of the multisystem nature of the clinical phenotypes.
2. Disorders of the pre-squalene cholesterol pathway
2.1 Mevalonate kinase deficiency
Mevalonate kinase phosphorylates mevalonate, the product of the reduction 
of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA), which is important in 
cholesterol biosynthesis and for farnesylation and isoprenylation of proteins [13]. 
Mevalonate kinase deficiency (MKD) is a recessively inherited autoinflammatory 
disorder in the isoprenoid biosynthetic pathway with a spectrum of manifestations, 
including the well-defined allelic clinical phenotypes of HIDS and MA [14], both of 
which were identified in the mid-1980s [15, 16].
Mevalonate kinase is essential for the biosynthesis of non-sterol isoprenoids, 
which mediate protein prenylation. MKD is caused by mutations in the MKD gene 
which encodes mevalonate kinase, with the degree of residual enzyme activity 
largely determining disease severity. MKD leads to perturbations in the mevalonate 
pathway of cholesterol synthesis with episodes of hyperinflammation [17]. MKD is 
now viewed as a phenotypic continuum based on the degree of enzyme deficiency, 
with MA the most severe phenotype and HIDS the mild end of the spectrum [18].
MKD is characterised by autoinflammatory flares with fever, abdominal pain, 
mucoid and cutaneous lesions and arthralgias [14]. The more severely affected 
patients with MA classically have developmental delay, dysmorphism, psycho-
motor retardation, hepatosplenomegaly and ocular abnormalities [14]. During 
attacks, patients with MKD have increased levels of acute-phase proteins including 
C-reactive protein and cytokines such as TNF-α, IL-6 and interferon-γ [19, 20]. The 
MA phenotype characteristically presents in the first few months of life, with ante-
natal presentations linked with a high rate of stillbirth [21]. Commonly reported 
dysmorphic features include frontal bossing, hypertelorism, long eyelashes and 
triangular-shaped facies, as well as failure to thrive, developmental delay, ataxia, 
seizures, myopathies and autoinflammatory attacks [21, 22]. MA is a multisystem 
phenotype with gastrointestinal manifestations including cholestasis and liver 
dysfunction [23], and ocular findings including recurrent conjunctivitis, cataracts 
and uveitis [24].
The HIDS phenotype typically presents with recurrent (four-to-six weekly) 
self-limited bouts of multisystem inflammation characterised by fever, abdominal 
pain, adenopathy, rash and arthralgia [14]. As these are common symptoms of 
many childhood infectious illnesses, the diagnosis of HIDS is often delayed for 
many years. HIDS episodes usually last 3–7 days, occurring in a cyclical fashion or 
induced by a provocative physiological stress such as illness, injury or vaccination. 
Acute abdominal pain may be the most marked and debilitating feature of systemic 
inflammation and can mimic a ‘surgical acute abdomen’ [24]. A long-term follow-
up study of 103 HIDS patients revealed that the frequency of the attacks decreases 
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over time, but 50% of patients greater than 20 years of age still experience six or 
more attacks per year, impacting on the quality of life [24].
The epidemiology of MKD is largely unknown. At least 300 people are docu-
mented worldwide, the majority with HIDS, although this is likely to be underdi-
agnosed as recurrent fevers in childhood are a common occurrence. The highest 
documented prevalence is in the Netherlands, with an estimated 1:200,000 affected 
nationwide, consequent to a high carrier rate which is estimated at 1:65 [24, 25].
Elevations in IgD in MKD are inconsistent and can be normal in up to 20% of 
cases [24]. Serum amyloidosis is a long-term sequela of prolonged inflammatory 
activation, with elevations in serum amyloid A noted in approximately 3% of 
HIDS patients [24]. Urinary excretion of mevalonic acid can persist in MA and 
maybe present in some HIDS patients during febrile attacks [21]. The diagnosis is 
confirmed by identifying pathogenic mutations in the MVK gene; currently more 
than 120 sequence variants in this gene have been reported in association with MKD 
[26], most of which are missense mutations that impair mevalonate kinase stability 
[27]. Some genotype-phenotype correlations exist: MVK variants located in the core 
of the protein (affecting folding and stability) are highly associated with the more 
severe MA phenotype [25, 28, 29]. In contrast, other variants such as the C-terminal 
V377I substitution typically manifest as the HIDS phenotype and are rarely associ-
ated with MA [25].
Although the precise pathogenesis of MKD remains unclear, increasing 
evidence suggests that deficiency in protein prenylation leads to innate immune 
activation and systemic hyperinflammation, which has assisted in the develop-
ment of cytokine-directed biologic therapy. Corticosteroids induce a complete 
response in 24% of HIDS patients [30]. Biologics targeting IL-1, including 
anakinra and canakinumab, and TNF-α blocking agents such as etanercept and 
adalimumab, have been used with varying success [30]. Some cases that have 
failed to respond to anakinra have demonstrated a successful reduction in symp-
toms with tocilizumab, a monoclonal antibody targeted against the IL-6 receptor 
[31]. One patient with MKD, treated with alendronate for steroid-induced osteo-
porosis, subsequently achieved complete remission [32]. Alendronate inhibits 
farnesol-pyrophosphate synthase. For refractory cases of MA phenotype, the last 
consideration for therapy includes liver transplantation or haematopoietic stem 
cell transplantation [14].
Blockade of the mevalonate pathway with the HMG-CoA reductase inhibitors 
reduces both mevalonic acid levels and residual isoprenoid production and but can 
trigger disease flares [22]. The inflammatory hyper-responsiveness in MKD appears 
to be due to lack of isoprenoid products and not accumulation of mevalonic acid. 
This appears to be due to the need for geranylgeranylation rather than other meval-
onate pathway products, such as cholesterol biosynthesis, in mediating the hyperse-
cretion of IL-1β [27]. The use of statins in this disease process has therefore largely 
been abandoned [30]. Mvk+/− mice do have some features of immune dysfunction, 
including increased serum IgD and TNF-α levels, as well as increased expression of 
activation markers on T-lymphocytes and macrophages [33].
2.2 Squalene synthase deficiency
Squalene synthase deficiency (SQSD) is a recently identified pre-squalene defect 
to have been characterised. In 2018, three patients were reported with this novel 
cholesterol biosynthesis defect [4]. Salient clinical features include facial dysmor-
phism, dry skin with photosensitivity, generalised tonic-clonic seizures, structural 
brain malformations, cortical visual impairment, profound global developmental 
delay and genital malformations in the two males [4].
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Gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic 
resonance spectroscopy profiles yielded a consistent and complex pattern of 
abnormal metabolites including accumulation of methylsuccinic acid, mevalonate 
lactone, mesaconic acid, 3-methyladipic acid, saturated and unsaturated branched-
chain dicarboxylic acids and glucuronides derived from farnesol [4]. A similar 
metabolite profile has previously been observed in the urine of animal models and 
humans treated with pharmacological inhibitors of squalene synthase, as well as 
in animals loaded with farnesol [10–12]. This urine metabolic profile is specific to 
and thus diagnostic of SQSD. Plasma total farnesol levels (the sum of free farnesol 
and farnesyl-pyrophosphate) in affected individuals were, however, significantly 
increased (1.5–3.9 mmol/L; reference <0.12) while plasma squalene levels were 
reduced or normal (0.17–0.93 mmol/L, reference 0.36–1.04).
A range of pathogenic FDFT1 molecular variants have been described in the 
three SQSD patients identified thus far (a sibship and an unrelated patient) 
[4]. The sibship was compound heterozygous for a maternally-inherited 120 kb 
deletion, resulting in loss of exons 6–10 of FDFT1 and the entire coding sequence 
of the neighbouring CTSB gene (encoding cathepsin B (OMIM 116810)); and 
a paternally inherited variant c.88024_88023delinsAG, which created a novel 
splice acceptor site. The unrelated patient was homozygous for a novel 16-bp 
intronic deletion. Functional characterisation of the variants demonstrated a 
partial splicing defect and altered promoter and/or enhancer activity, reflecting 
essential mechanisms for regulating cholesterol biosynthesis and/or uptake in 
steady state [4].
Fdft1-null mice demonstrate embryonic lethality at day 12.5 in conjunction with 
growth restriction and neurodevelopmental disorders [34]. The fact that the FDFT1 
variants in the human SQSD cases are compatible with life may be explained by the 
fact that all individuals have some form of residual FDFT1 activity, either resulting 
from the diminished levels of correctly-spliced enzyme or by functional compensa-
tion for disrupted regulation [4].
2.3 Lanosterol synthase deficiency
In the cholesterol biosynthesis pathway, lanosterol synthase leads to the cyclisa-
tion of (S)-2,3-oxidosqualene into lanosterol. Pathogenic mutations in the LSS gene 
have recently been reported in a spectrum of clinical phenotypes including con-
genital cataracts in three families [35], hypotrichosis simplex (HS) in three families 
[36] and a more severe neuroectodermal syndrome formerly named alopecia with 
mental retardation (APMR) syndrome in six unrelated families [37]. HS (OMIM 
618275) is a rare form of hereditary alopecia characterised by childhood onset of 
diffuse and progressive scalp and body hair loss [36]. APMR syndrome (OMIM 
203650) is a rare disorder with autosomal recessive transmission. A recent report 
identified 11 individuals from seven unrelated families affected with alopecia, male 
genital abnormalities, variable MRI abnormalities and neurological symptoms 
[37]. In this cohort, total alopecia was universal with other common dermatological 
manifestations including ichthyosis and erythroderma. Neurological manifestations 
included significant developmental delay, microcephaly, epilepsy and hypomyelin-
ation [37].
Sterol profiling in lanosterol synthase deficiency cases has not identified any 
specific abnormalities, thus supporting the previously proposed hypothesis of an 
alternative cholesterol pathway [36]. LSS variants identified to date include trun-
cating, missense and splicing variants. LSS has also been associated with congenital 
cataracts in rat [38]. Mice homozygous for the Lsstm1b(KOMP)Wtsi allele demonstrate 
variable lethality, from embryonic day 9.5 to postnatal prior to weaning [39].
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3. Disorders of the post-squalene cholesterol pathway
3.1 Hydrops-ectopic calcification-moth-eaten skeletal dysplasia
Most proximal in the post-squalene pathway is hydrops-ectopic calcification-moth-
eaten (HEM) skeletal dysplasia, or Greenberg dysplasia. This very rare and severe 
autosomal recessive disorder was first described in 1988 [40] with only 11 examples 
identified in the literature to date. All but one of these have been lethal in utero, with 
the remaining case dying at 2 days of age [41]. HEM skeletal dysplasia is characterised 
by significant non-immune hydrops fetalis, erroneous chondro-osseous calcification of 
vertebrae, ribs, pelvis, larynx and trachea as well as a diagnostic mottled ‘moth-eaten’ 
appearance of long bones on radiography [42–44]. Further skeletal abnormalities can 
include rhizomelic and mesomelic shortening of the limbs, platyspondyly, decreased 
skull ossification and distal dysmorphisms such as absent phalanges or postaxial poly-
dactyly [42–45]. Non-skeletal congenital malformations include pulmonary hypoplasia, 
intestinal malrotation, cystic hygroma and excessive extramedullary haematopoiesis 
[45, 46]. Histology shows significant bone and cartilage disorganisation [43, 45].
HEM skeletal dysplasia was first suggested as an inborn error of cholesterol 
biosynthesis by Kelley et al. [47] with identification of increased levels of 
4,4-dimethylcholesta-8 [9],14-dien-3 β -ol and 4,4-dimethylcholesta-8(9),14,24-
trien-3 β -ol in cultured fibroblasts, indicating a deficiency of sterol ∆14-reductase. 
This enzyme converts these sterols to 4,4-dimethylcholesta-8(9)-en-3 β -ol and 
4,4-dimethylcholesta-8(9),24-dien-3 β -ol, respectively. This point on the choles-
terol biosynthesis pathway is unique with sterol ∆14-reductase activity by both 
the lamin B receptor (LBR) and a second enzyme DHCR14 (TM7FS2), although 
functional redundancy is disputed [48, 49]. It was originally thought that the more 
prominent role in sterol biosynthesis was that of DHCR14 compared to the lamin B 
receptor. However, it has more recently been demonstrated that it is a deficiency in 
the lamin B receptor due to mutations in LBR at 1q42.12 that is causative for HEM 
skeletal dysplasia [50, 51] and that it is the LBR, not DHCR14, that is required for 
cholesterol biosynthesis [48, 52].
The involvement of LBR has raised contention as to whether HEM skeletal 
dysplasia should be classified as a laminopathy rather than as an error of cholesterol 
synthesis [49]; however, it is appropriate to recognise that mutations in LBR can cause 
different disorders in different contexts. The type of mutation (missense, nonsense or 
splice-site), the functional location of each mutation in the LBR gene and the residual 
protein activity affect the clinical outcome of this disorder [53, 54]. The LBR protein 
has both a nuclear domain involved in anchoring chromatin to the nuclear membrane, 
and a transmembrane domain with sterol ∆14-reductase activity critical for choles-
terol synthesis [48], the latter primarily where mutations causing HEM dysplasia 
are located [50]. Some mutations found in LBR in HEM dysplasia patients have been 
identified in the heterozygous state in the relatively benign autosomal dominant condi-
tion of Pelger-Huët anomaly in which granulocytes have bilobed nuclei but patients are 
otherwise clinically normal. These two conditions may represent different allele pat-
terns of the same disorder for some mutations [53, 55]. The less common homozygous 
Pelger-Huët is clinically more severe with round or ovoid granulocyte nuclei and some 
cases with mild skeletal abnormalities [56, 57]. This highlights the role of the lamin 
B receptor sterol reductase function as essential in prenatal development but also the 
phenotypic continuum that can occur for various allele combinations of the LBR gene.
Species variation with respect to the role of the LBR can make mouse model 
outcomes difficult to elucidate. Studies of mutations in both LBR and DHCR14/
TM7FS2 have been investigated in ichthyosis (ic) mice with contrasting conclusions, 
including those highlighted above and as reviewed by Herman and Kratz [58].
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3.2  Congenital hemidysplasia with ichthyosiform erythroderma and limb 
defects syndrome
Congenital hemidysplasia with ichthyosiform erythroderma and limb defects 
(CHILD) syndrome is a rare X-linked dominant disorder of cholesterol biosynthesis, 
with fewer than 100 cases discussed in the literature [58]. The earliest identifica-
tion of the condition is thought to be in 1903 [59], through the proposal of the 
syndromic acronym in 1980 [60]. CHILD syndrome is nearly always male-lethal 
although perhaps two males with this syndrome have been identified, one with a 46, 
XY karyotype, postulated to have survived due to a postzygotic mutation [61]. The 
distinguishing hallmark of the condition is that of unilateral skin lesions with ipsi-
lateral limb defects [60, 62, 63]. The characteristic yellow, scaly plaques are usually 
present at birth or emerge in the first few months of life and while there may be some 
resolution over time, they often remain for life [60]. These markings may follow the 
lines of Blaschko, but more commonly, there is a striking delineation at the midline 
with the lesions showing a unique lateralisation pattern [62]. This has been proposed 
to be due to interactions between X-inactivation and the organisation of left-right axis 
symmetry in the developing embryo [60]. The lateralisation of these lesions and their 
persistence is a distinguishing feature of CHILD syndrome compared to differentials 
such as CDPX2, a similar but distinct inborn error of cholesterol biosynthesis [64].
CHILD syndrome demonstrates complete limb aplasia, severe phocomelia or 
severe hypoplasia on the same side of the body as ichthyosiform lesions [60]. Infant 
radiography may show epiphyseal stippling such as that seen in CDPX2, as well as 
milder skeletal malformations such as scoliosis, hypo or hemi-plastic vertebrae, 
distal digit shortening, syndactyly or polydactyly [65]. Non-skeletal manifesta-
tions include alopecia, verruciform xanthoma, dystrophic nails and congenital 
malformations on the affected side that can involve the heart, kidneys and CNS 
[60, 65]. Intelligence may be normal or slightly reduced. Despite the severity of 
these symptoms, mild cases of CHILD syndrome with no skeletal and/or cutaneous 
involvement have been identified through molecular analysis [66].
Molecular investigation has identified various mutations in the NSDHL (NADH 
steroid dehydrogenase-like) gene as causative for CHILD syndrome [67]. NSHDL is 
located at Xq28 and encodes 3 β -hydroxysteroid dehydrogenase, part of a three-part 
enzyme complex. This C4 demethylation complex acts on the sterol ring in the post-
squalene pathway, converting 4,4-dimethylcholesta-8(9),24-dien-3β-ol to zymo-
sterol and 4,4-diemthylcholesta-8(9)-en-3β-ol to cholesta-8(9)-en-3β-ol. Mutations 
are most often loss-of-function [68]. Cholesterol and sterol levels are normal and so 
a diagnosis requires clinical and molecular assessment. Various NSDHL mutations 
have been studied in the allelic ‘bare patches’ (Bpa) and ‘striated’ (Str) murine mod-
els [69]. These have given insights into facets of CHILD syndrome and cholesterol 
synthesis disorders in general, for example, the roles of the maternal placenta [70] 
and Hedgehog signalling pathways [71] in disease presentation.
Treatment options for CHILD syndrome have generally focused on topical 
management of skin lesions with symptomatic remedies such as emollients or with 
pathogenesis-based therapies generally involving combinations of cholesterol and a 
cholesterol synthesis-inhibitor [72, 73], the latter with some efficacy.
3.3 X-linked dominant chondrodysplasia punctata 2
X-linked dominant chondrodysplasia punctata 2 (CDPX2), or Conradi-
Hünermann-Happle syndrome, is estimated to have an incidence of 1/400,000 
and, similarly to CHILD syndrome, is almost entirely male-lethal. The CDPX2 
phenotype, like the other cholesterol biosynthesis disorders, is heavily based on the 
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skeletal and cutaneous domains, and there can be significant variability even within 
family lines [74–76] with generational anticipation [74]. Severe manifestations can 
result in neonatal or infant death with considerable skeletal and internal abnormali-
ties, while mild cases may be nearly asymptomatic. This range of phenotypic vari-
ability is likely due to the combination of somatic and/or gonadal mosaicism and 
X-inactivation patterns [76]. Occasional male patients are identified with CDPX2, 
usually due to somatic mosaicism [77, 78] with one case of 46,XXY [79]. Gonadal 
mosaicism is possible which is relevant for recurrence risk [80].
Widespread epiphyseal stippling is seen on infant radiographs, often including 
not just the long bones but the trachea and vertebrae as well [81–83]. Additional 
skeletal stigmata include short stature and scoliosis (which can be congenital), club-
foot, joint contractures, and postaxial polydactyly [74, 77, 83]. Cutaneous mani-
festations include skin with patches of scaly hypo or hyper-pigmentation, which 
usually follows the lines of Blaschko. The initial skin scaling and erythroderma 
present at birth usually fades over the first few months of life, leaving follicular 
atrophoderma, pigmentation and alopecia, although ichthyosis can persist [84, 85]. 
The pattern and then resolution of skin scaling as well as its histological profile is 
a differentiating diagnostic feature for CDPX2 compared to CHILD syndrome. 
Diagnosis of CDPX2 in adulthood can be difficult due to the childhood resolution 
of the characteristic skin lesions and epiphyseal stippling [86]; however, a combina-
tion of cutaneous manifestations, asymmetric limb reduction and cataracts (found 
in 65% of patients) is a good suggestion of this condition for further investigation 
[86]. CDPX2 presents with characteristic facial features including frontal bossing, 
midface hypoplasia and flat nasal bridge [74, 81]. The condition is also associated 
with microphthalmia or microcornea, congenital heart disease, renal abnormali-
ties including hypoplasia and hydronephrosis and sensorineural hearing loss [87]. 
Cognition is usually normal [87].
CDPX2 is caused by mutations in the EBP (emopamil binding protein) gene [88, 89] 
located at Xp11.23 and encoding a Δ8-Δ7-sterol isomerase. This enzyme functions 
downstream of the C4-demethylation complex affected in CHILD syndrome and 
converts zymosterol and cholesta-8(9)-en-3 β -ol to cholesta-7,24-dien-3 β -ol and 
lathosterol, respectively. There is a phenotypic correlation with enzyme function 
with lethality of homozygous females and clinically affected heterozygous females; 
however, there is no clear genotype-phenotype correlation, presumably due to 
X-inactivation patterns [74, 76]. Surviving males with CDPX2 are almost always 
due to mosaic postzygotic mutations as a hemizygous male genotype is lethal 
in utero. CDPX2 mutations (including deletions, insertions, nonsense, missense and 
splice-site) of EBP have been identified as both de novo and inherited mutations 
and are found throughout the entire length of the gene [74].
While there is no clear CDPX2 genotype-phenotype correlation, there is a 
distinct association between genotype and CDPX2 sterol profile [74], and plasma 
sterol assay is a highly specific indicator for an EBP mutation [83]. Plasma shows 
increased 8-dehydrocholesterol and 8(9)cholesterol levels, with the ratios compared 
to cholesterol increased 0.71–0.80% [74]. Plasma cholesterol is usually normal. 
Treatment and surveillance are symptomatic, and studies in these areas have been 
advanced by the ‘tattered’ (Td) mouse which shares both phenotypic and molecular 
similarities with human CDPX2 [89].
3.4 Lathosterolosis
Lathosterolosis (OMIM 607330) results from impaired 3-hydroxysteroid-
5-desaturase (SC5D) activity [90]. In the Kandutsch-Russel synthetic pathway, 
SC5D catalyses the conversion of lathosterol to 7-dehydrocholesterol (7DHC) 
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in the enzymatic step immediately preceding the defect in SLOS, whereas in the 
Bloch pathway of cholesterol synthesis, SC5D catalyses the conversion of cholesta-
7,24-dienol to 7-dehydrodesmosterol [90].
To date, deleterious missense mutations of SC5D have been reported in six 
patients from three families [91–95]. The clinical features include microcephaly, 
facial dysmorphism, bitemporal narrowing, ptosis, cataracts, anteverted nares, 
micrognathia, postaxial polydactyly, syndactyly, ambiguous genitalia, non-
neuronal mucolipidosis, global developmental delay, intellectual impairment, 
hepatic cirrhosis, and early lethality [91–95]). One surviving patient who developed 
end-stage hepatic failure and received a liver transplantation had improvement of 
lathosterolosis symptoms [96]. Another patient had a milder clinical phenotype 
of microcephaly and learning defects with cataracts [91] highlighting the possible 
under-diagnosis of the syndrome without plasma sterol analysis.
Plasma cholesterol levels are normal with accumulation of lathosterol in plasma 
and in cultured fibroblasts, and lamellar inclusions within cellular lysosomes [95]. 
Sc5d−/− pups are stillborn and demonstrate craniofacial malformations including 
cleft palate and limb defects such as postaxial polydactyly [94].
3.5 Smith-Lemli-Opitz syndrome
Smith-Lemli-Opitz syndrome (SLOS) is the prototypical inborn error of choles-
terol biosynthesis first described in 1964 [97]. It is by far the most common disorder 
in this group, with an incidence of approximately 1/40,000 although this can range 
from 1/70,000 to 1/10,000 depending on the population in question [98]. The car-
rier frequency can range from approximately 1:100 in North American Caucasians to 
1:50–1:30 in various Central European populations [99]. While these carrier rates would 
imply a far greater incidence than is clinically observed, there is thought to be a level of 
misdiagnosis or non-diagnosis in mildly-affected patients, and in utero prenatal demise is 
estimated to affect 42–88% of conceptuses [100], mostly in the first trimester [98, 101].
SLOS has a broad range of phenotypic variabilities: mild cases can comprise 
minor physical abnormalities and behavioural or learning difficulties through a 
wide spectrum to a severe phenotype comprising major and life-limiting congenital 
abnormalities. Cognition can range from near-normal [102] to profound intel-
lectual impairment, and on MRI, up to 96% of SLOS patients have a structural 
brain abnormality [103]. There is a correlation of atypical sterol profiles with both 
intellectual impairment and brain malformations, particularly abnormalities of 
the septum pellucidum and corpus callosum [103]. CNS myelination is normal 
despite its high proportion of cholesterol content and the mostly in situ synthesis 
of cholesterol in the CNS [104]. As well as intellectual impairment, patients are 
often diagnosed with language delays or impairment, autistic spectrum disorder 
and sleep disturbances, and can engage in self-harm. Global developmental delay, 
hypotonia and failure to thrive are common [105–107]. The most common physical 
manifestation reported with SLOS is that of 2,3 toe syndactyly, and a combination 
of this with other structural or cognitive symptoms should suggest a possible SLOS 
diagnosis for investigation [108]. Limb anomalies are common, including polydac-
tyly, short proximal thumbs and a single palmar crease [105–107]. Other structural 
malformations that can occur include microcephaly, cleft palate, bifid uvula and 
characteristic facies with micrognathia, ptosis and broad nasal tip with anteverted 
nares [105–107]. This facial dysmorphia can be less recognisable in older patients 
[107]. Congenital abnormalities can also affect the heart and lungs, gastrointestinal 
tract and genitalia [105–107]. Patients with SLOS often have severe ultraviolet 
photosensitivity [109].
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The final steps of the post-squalene cholesterol biosynthesis pathway are con-
version of 7-dehydrodesmosterol to desmosterol and 7-dehydrocholesterol (7-DHC) 
to cholesterol. The latter is catalysed by the 3 β -hydroxysteroid-Δ7-reductase (or 
7-dehydrocholesterol reductase, DHCR7) enzyme, encoded by the DHCR7 gene 
at 11q13.4. Increased levels of 7-DHC and decreased levels of cholesterol led to 
SLOS being identified as a disorder of sterol biosynthesis in 1993 [110, 111]. This 
altered plasma profile is a useful diagnostic tool for SLOS, and there is evidence of a 
relationship between serum sterols and disease severity [112, 113].
Over 100 mutations in DHCR7 have been identified in SLOS [114] with no clear 
genotype-phenotype correlations [115, 116], although some mutations are associ-
ated with more mild phenotypes due to some residual enzyme activity [117]. There 
is a significant correlation between SLOS patient phenotype and maternal genotype 
for ApoE and ABCA1 [118, 119]. These correlations are positive for amelioration 
of SLOS symptomatology and pathogenesis and with the potential for therapeutic 
mediation [120].
As well as being the precursor to cholesterol, 7-DHC is also the precursor to vita-
min D with exposure of cutaneous 7-DHC to ultraviolet B and subsequent synthesis 
to vitamin D by the liver and kidney. Increased levels of circulating vitamin D are 
seen in patients with SLOS [121], despite their increased photosensitivity and ensu-
ing limited sun exposure. One of the primary theories for a possible heterozygous 
advantage of DHCR7 mutations is that of protection against vitamin D deficiency 
[105], particularly given the greater carrier rate seen in populations of northern 
Europe [98, 99].
A prenatal diagnosis can be obtained via molecular or biochemical analysis 
(e.g. of amniotic fluid sterols [122]); however, non-invasive techniques can also 
identify pregnancies requiring SLOS investigation. Measurement of a low mater-
nal serum unconjugated estriol (uE3), particularly when combined with abnor-
mal sonography results, can be utilised for prenatal screening although this can 
yield false positive results and uE3 levels can also be predictive for other disorders 
[101]. Baseline screening for a SLOS-affected pregnancy is also possible non-
invasively via serial measurement of steroids such as pregnanetriol in maternal 
urine [123, 124]. Abnormal plasma sterol ratios in unaffected heterozygotes [125] 
mean that carrier status may be determined prior to pregnancy for increased 
reproductive options.
Current treatment protocols for SLOS usually involve endogenous cholesterol 
supplementation with or without adjunct therapies such as simvastatin [126]. There 
is broad anecdotal evidence throughout the literature as to the positive benefit of 
cholesterol supplementation for patient growth, overall health (including improved 
photosensitivity and response to infection) and behaviour, as well as measurable 
changes towards typical plasma sterols [127–129]. These improvements have been 
reported following initiation of cholesterol treatment in both children and adults 
[130], although with greater rate of improvement with earlier intervention [131]. 
Limitations to the efficacy of cholesterol treatment certainly exist, such as choles-
terol’s inability to cross the blood-brain barrier in any practical quantity (which 
makes the apparent behavioural improvements reported interesting). The real 
value of cholesterol supplementation is yet to be definitively determined as trials of 
increased dietary cholesterol both with and without placebo controls have yielded 
very mixed results [132–134]. Antioxidant [135, 136] and virus vector [137] thera-
pies have also been explored as an avenue for improved patient outcomes for SLOS 
and other disorders of cholesterol synthesis. Both mouse and rat models of null and 
hypomorphic alleles in DHCR7 have been useful homologues for characterisation 
and investigation of human SLOS [138, 139].
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3.6 Desmosterolosis
Desmosterolosis (OMIM 602398) is currently the final inborn error of cholesterol 
biosynthesis and is caused by defective enzymatic function of 3-hydroxysterol-delta 
24-reductase (DHCR24). This reaction causes the reduction of the C-24 bond in the 
aliphatic side chain of cholesterol [140]. Reduction of the C-24 bond catalysed by 
DHCR24 can occur at different times in the cholesterol synthetic pathway: this step 
occurs early in the Kandutsch-Russel cholesterol synthetic pathway [6] but is the 
penultimate step in the Bloch pathway of cholesterol synthesis [5].
While first described in 1998, the molecular mechanisms of desmosterolosis 
were not characterised until 2001 [140, 141]. To date, only nine cases have been 
reported and clinical features include SLOS-like dysmorphism, thick alveolar 
ridges, gingival nodules, cleft palate, short limbs, severe congenital heart defect, 
atherosclerosis, arthrogryposis, ambiguous genitalia, microcephaly, agenesis of 
the corpus callosum, global developmental delay and intellectual impairment 
[141–147]. The diagnosis of desmosterolosis is made by demonstrating elevated 
levels of desmosterol by GC-MS analysis, with serum cholesterol levels usually 
normal [141, 142]. Reported DHCR24 pathogenic mutations thus far have all been 
missense mutations.
A targeted mouse model for desmosterolosis has been generated, and Dhcr24−/− 
mice are viable with some postnatal growth retardation and infertility [148]. 
Pharmacological inhibitors of DHCR24 have been developed for studies in rat 
models [135, 149, 150]. Treatment of pregnant rats with these inhibitors of sterol-
D24-reductase is teratogenic and produces cataracts, CNS abnormalities, genitouri-
nary and skeletal anomalies [149–151].
4. Cholesterol biosynthesis genes in other Mendelian diseases
Inherited defects in genes encoding cholesterol biosynthetic enzymes or regula-
tors of cholesterol homeostasis create severe clinical phenotypes as discussed above 
and highlighted in Table 1. The central nervous system is highly susceptible to 
perturbations in cholesterol biosynthesis, with manifestations including structural 
brain malformations, defects in myelin structures and, in some cases, profound 
developmental delay. While the cholesterol biosynthesis defects are genetically 
distinct individual disorders, their characterisation has demonstrated interrelation 
between human disease processes. This underscores the importance of choles-
terol in normal cellular function and opens the possibility of novel therapies for 
Mendelian disorders associated with cholesterol synthesis, transport and regula-
tion. Lessons learnt from abrogation of the cholesterol biosynthesis pathway, either 
by deliberate pharmacological manipulation or via inherited Mendelian diseases, 
serve to provide vital information amongst a raft of seemingly unrelated human 
disease such as inflammatory bowel disease (IBD), the cholesterol trafficking 
disorders Niemann-Pick disease type C (NPC, OMIM 257220) and Tangier disease 
(TD, OMIM 205400) and neurodegenerative diseases such as Alzheimer’s disease 
(OMIM 104300).
NPC is an autosomal recessive lysosomal storage disorder of cholesterol traf-
ficking due to mutations in the NPC1 and NPC2 genes [152]. NPC1 encodes a 
13-transmembrane-spanning protein in late endosomes/lysosomes, while NPC2 
encodes a soluble lysosomal cholesterol-binding protein [153]. This is a devastat-
ing disease characterised by a relentless neurodegenerative disease course that is 
usually fatal in the second decade of life, although a subset of patients will die in 
infancy consequent to hepatic or pulmonary failure [152]. Free cholesterol is stored 
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in the late endosome/lysosome with minimal escape of cholesterol from the acidic 
compartment to the endoplasmic reticulum. NPC leads to a block in trafficking/
fusion essential for the functioning of the endosomal/lysosomal system, causing the 
secondary storage of cholesterol, glycosphingolipids and sphingomyelin [154]. It is 
likely that cholesterol accumulation is a secondary storage metabolite in NPC [154].
TD has been reported in approximately 100 patients and is caused by mutations 
in the gene encoding ABCA1 [155, 156]. Patients have minimal circulating HDL and 
accumulate cholesterol, leading to the formation of foam cells and the development 
of cardiovascular disease, orange-coloured tonsils, enlarged spleen, liver and lymph 
nodes and peripheral neuropathy. The membrane-associated protein ABCA1 regu-
lates cellular cholesterol and phospholipid homeostasis by functioning as a cholesterol 
efflux pump [157]. Tangier disease patients have structurally abnormal late endocytic 
vesicles, which are also observed in the cells of patients with NPC disease [158]. 
There exists a link between ABCA1 expression and function with the NPC pathway 
[158, 159]. NPC disease is characterised at the cellular level by storage of glycosphin-
golipids, fatty acids, cholesterol, sphingomyelin and sphingosine. NPC cells also have 
low levels of calcium in the late endosome/lysosome. These cellular hallmarks were 
also identified in TD patients, suggesting that the loss of function of ABCA1 inhibits 
the NPC pathway through an unknown mechanism. A recent serendipitous clinical 
observation has provided a further link between TD and the NPC pathway: an adult 
patient thought to have NPC1 was treated with miglustat and demonstrated measur-
able clinical improvements in neurological and haematological parameters. TD was 
ultimately diagnosed when the molecular investigations for NPC were negative [160].
SLOS cellular pathophysiology should theoretically be correctable with choles-
terol replacement therapy, as this should bypass the enzymatic defect in the conver-
sion of 7DHC to cholesterol. However, when SLOS patient fibroblasts are cultured 
in a lipid-depleted medium to induce de novo cholesterol synthesis, cells exhibit a 
significant cholesterol trafficking defect leading to the accumulation of unesterified 
cholesterol in the late endosome/lysosome, which mimics the fate of LDL-derived 
cholesterol in NPC cells [161]. This proposes a possible mechanistic convergence 
between these very different inborn errors of metabolism. 7DHC could be interfer-
ing with the function of NPC1 and NPC2 by inhibition, akin to the U18666A drug 
that induces NPC cellular phenotypes [162]. In SLOS patient fibroblasts, accumula-
tion of 7DHC led to the accumulation of metabolic indicators of NPC, that is, the 
lysosomal storage of cholesterol, sphingomyelin and multiple glycosphingolipids 
[163]. Elevated sphingosine levels in SLOS patient cerebrospinal fluid have been 
described. This serendipitous discovery of a link between the NPC pathway, two 
cholesterol trafficking disorders and the prototypic cholesterol biosynthesis defect 
SLOS will prove important in delineating the pathogenesis of these diseases and 
the development of novel therapies. Miglustat is an iminosugar drug that inhibits 
glucosylceramide synthase, the enzyme that catalyses the first step in glycosphin-
golipid biosynthesis, and it is in use as a substrate reduction therapy for a number 
of lysosomal storage defects including NPC [164]. The finding that SLOS and TD 
involve secondary inhibition of the NPC pathway suggests that miglustat could be a 
novel therapy for SLOS and TD.
The recently described SQSD exhibits a characteristic sterol pattern dominated 
by farnesol-derived dicarboxylic acids secondary to accumulation of farnesol-PP 
proximal to the enzymatic block. The role of these metabolites in the pathogenesis 
of this rare disease remains to be determined but is of interest as farnesol and its 
products exhibit a wide variety of biological activities including cell growth inhibi-
tion, induction of apoptosis and regulation of bile acid secretion [165]. Evidence 
is emerging that dysregulation of the mevalonate pathway may be involved in the 
progression of neurodegeneration in disorders such as Alzheimer’s disease [166].
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Inflammatory bowel disease (IBD) comprises a spectrum of phenotypes from 
Crohn’s disease to ulcerative colitis. IBD usually occurs in young adults; however, 
onset in infancy and childhood are described. IBD occurs both in isolation and in 
monogenic syndromes with early-onset autoinflammation including the NOD2, 
ATG16L1, IL23R, IL10R, IL10 and XIAP genes which have previously been cor-
related with IBD both in multifactorial and in Mendelian models [167]. MVK 
mutations may perhaps then synergistically augment the risk of developing IBD, 
especially as severe neonatal onset colitis responsive to anakinra has been reported 
as a feature of MVK deficiency [14, 168, 169].
Recent studies have implicated the accumulation of pre-cholesterol sterols and 
the replacement of cholesterol with some of these sterols in lipid rafts as playing a 
key role in the underlying pathophysiology of cholesterol synthesis defects [170]. 
The meiosis-activating sterols were the first group of cholesterol biogenesis inter-
mediates that were found to have important extrahepatic functions in mammals. 
Mutations in sterol-C4-methyl oxidase-like gene (SC4MOL) are causative for a rare 
autosomal recessive syndrome associated with psoriasiform dermatitis, arthralgias, 
congenital cataracts, microcephaly and developmental delay [171, 172]. This gene 
encodes a sterol-C4-methyl oxidase (SMO) which catalyses demethylation of 
C4-methylsterols in the cholesterol synthesis pathway [172]. C4-methylsterols are 
meiosis-activating sterols, and further work is required to understand the role of 
these novel biomolecules in the pathogenesis of the cholesterol biosynthesis defects.
5. Conclusion
Inborn errors of cholesterol metabolism have provided many fundamental 
insights into normal cholesterol homeostasis and cell biology over several decades. 
These disorders have been viewed as discrete diseases with their own unique 
genetic, biochemical and cellular consequences that in turn cause the clinical spec-
trum of symptoms associated with each disease. There remain specific pre-squalene 
enzymatic defects to be characterised and many unanswered questions regarding 
the pathogenesis of the cholesterol biosynthesis defects. What has been surprising 
is that at least three cholesterol-related disorders (SLOS, NPC and TD) all share a 
common pathological inhibition of the NPC pathway. The precise mechanism that 
inhibits this pathway in SLOS and TD remains to be fully elucidated, but these find-
ings are suggestive of novel therapeutic approaches to treating SLOS and TD using 
drugs that modify the cell biology of NPC such as miglustat. Whether other human 
diseases also involve NPC pathway dysfunction remains to be determined. Current 
investigation of this question may pave the way for novel approaches to therapy for 
diseases that currently lack effective treatments.
MA, mevalonic aciduria; HIDS, hyper IgD syndrome; SQSD, squalene syn-
thase deficiency; LSS, lanosterol synthase deficiency; HEM, hydrops-ectopic 
calcification-moth-eaten; CHILD, congenital hemidysplasia with ichthyosiform 
erythroderma and limb defects; CDPX2, X-linked chondrodysplasia punctate 2; 
SLOS, Smith-Lemli-Opitz syndrome; DD, developmental delay; II, intellectual 
impairment; CHD, congenital heart defect; AR, autosomal recessive; XLD, 
X-linked dominant.
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